Fierce Pharma
FEBRUARY 13, 2024
While Biogen’s financials are in rough shape now, the company’s CEO, Chris Viebacher, sees reason to be optimistic about the future. | With four new drug launches rolling and the majority of the company’s losses of exclusivity in the rearview, Biogen figures it could chart continued revenue growth over the next 10 years, CEO Chris Viehbacher said Tuesday.
MedCity News
FEBRUARY 13, 2024
Exscientia’s termination of CEO Andrew Hopkins is for cause and effective immediately. Grounds for termination include misconduct or behavior that brings Hopkins or the company into disrepute, according to his employment agreement.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
FEBRUARY 13, 2024
It’s the approval Ipsen has been waiting for since buying up Onivyde in 2017. | It’s the approval Ipsen has been waiting for since buying up Onivyde in 2017. The FDA has approved Onivyde as part of a combination dubbed Nalirifox to treat patients with newly diagnosed metastatic pancreatic cancer.
pharmaphorum
FEBRUARY 13, 2024
Biogen’s Skyclarys is the first approved medicine for the inherited neurological disease Friedreich’s ataxia (FA) in the EU, after getting a green light from the European Commission.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
FEBRUARY 13, 2024
After introducing legislation targeting certain Chinese biopharma companies, a group of bipartisan lawmakers are taking their concerns to the White House—and upping the stakes. | After proposing a bill to revoke funding from certain Chinese biopharmas, a group of bipartisan legislators penned a letter to certain White House officials pressing for sanctions on the two companies based on alleged links to China's Communist Party and its military.
MedCity News
FEBRUARY 13, 2024
There is some acknowledgment by employers of their pain problem, but this awareness is not universal. This demonstrates a clear need for solutions that tackle not only health care costs, but absenteeism, the impact to presenteeism, and overall productivity.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
MedCity News
FEBRUARY 13, 2024
Proper data collection, analysis, and utilization has the potential to address long-standing health disparities and propel our healthcare system forward to serve all communities.
Fierce Pharma
FEBRUARY 13, 2024
A federal judge has tossed a lawsuit by industry lobbying group PhRMA which challenged the legality of Medicare price negotiations.
pharmaphorum
FEBRUARY 13, 2024
Researchers have used proteomics data from the UK Biobank to identify protein biomarkers in blood that could give warning of dementia years before diagnosis
Fierce Pharma
FEBRUARY 13, 2024
It appears GSK won’t have to fork over extra Zejula royalties to AstraZeneca after all, thanks to an appeals court victory in the companies’ long-running U.K. legal dispute. | GSK was previously ordered to pay rival PARP inhibitor maker AstraZeneca a larger share of total sales on its cancer med Zejula. But an appeals court has overturned the decision.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
pharmaphorum
FEBRUARY 13, 2024
Texas judge has thrown out the first lawsuit brought by PhRMA claiming Medicare negotiation of drug pricing is unconstitutional
European Pharmaceutical Review
FEBRUARY 13, 2024
The first CRISPR/Cas9 gene-edited therapy has been granted a marketing authorisation by the European Commission (EC). Vertex Pharmaceuticals’ CASGEVY ( exagamglogene autotemcel [exa-cel]) is conditionally approved individuals 12 years and over with severe sickle cell disease characterised by recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.
Pharmaceutical Technology
FEBRUARY 13, 2024
The MHRA kicks off phase two of the Yellow Card biobank to explore the genetic link to side effects of direct oral anticoagulants.
MedCity News
FEBRUARY 13, 2024
Headlight’s funding round was led by Matrix and EPIC Ventures. The company also hired new leadership, including CEO Geoff Swindle, who was formerly chief business officer at PillPack and Amazon Pharmacy.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
Pharmaceutical Technology
FEBRUARY 13, 2024
The regulatory greenlight makes it the only gene therapy available in Europe for sickle cell disease and TDT.
MedCity News
FEBRUARY 13, 2024
The conference is the premier boutique healthcare investment event in the U.S.
European Pharmaceutical Review
FEBRUARY 13, 2024
In January, United States Pharmacopeia (USP) published revisions to previous drafts of chapters about using rapid microbiological methods (RMM), with a specific focus on short-life products. <72> Respiration-Based Microbiological Methods for the Detection of Contamination in Short-Life Products The changes for the proposed chapter the detection of contaminants in short-life products.
pharmaphorum
FEBRUARY 13, 2024
Roche has turned to artificial intelligence specialist PathAI to accelerate its development of digital pathology technologies that can be used to match patients with drug treatments and support new drug development. The alliance is with Roche Tissue Diagnostics (RTD), a unit of the Swiss pharma group that is concerned with the development of tissue-based tools to improve the diagnosis of cancer and grew out of Roche’s acquisition of Venta Medical Systems in 2008.
Evolve Your Success
FEBRUARY 13, 2024
The biggest challenges in our lives should not stop us in our tracks, but rather open up new possibilities for a more meaningful life. Cancer survivor Rob Ciaramirato fully embraced this mindset, unleashing a more purposeful version of himself after going through one of his biggest tests. In this special episode for World Cancer Day, he joins Samuel Adeyinka in looking back how being diagnosed and surviving cancer made him realize the purposeful things he can do through medical sales.
PharmaVoice
FEBRUARY 13, 2024
As backlash builds for the recently announced matchup, critical questions remain over its impact.
Pharmacy Times
FEBRUARY 13, 2024
If approved, this would mark the first MDMA-assisted therapy and psychedelic-assisted therapy approved, calling for a reschedule of MDMA from Schedule I. A PDUFA was set for this summer.
Pharmaceutical Technology
FEBRUARY 13, 2024
Research indicates that designing clinical trials with the patient in mind reduces recruitment times and enhances trial performance.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
Pharmacy Times
FEBRUARY 13, 2024
The findings suggest that 6 months after vaccination with ARCT-154, individuals had a longer immune response.
Clarify Health
FEBRUARY 13, 2024
In healthcare, the ability to predict future demand with precision is not just a competitive advantage. For many hospitals and healthcare systems, it’s a necessity for survival. Optimizing resources to meet the moment calls for strategic planning powered by healthcare data analytics and effective demand forecasting. Demand forecasting in the context of hospital systems is critical for aligning resources like staff, equipment, and beds with future patient care needs.
Pharmacy Times
FEBRUARY 13, 2024
Pharmacists are uniquely positioned to play a frontline role in advancing health equity. This will require, however, that we build the pipeline of future pharmacists and preserve vital community touchpoints.
Pharmaceutical Commerce
FEBRUARY 13, 2024
Various considerations can help pharmaceutical manufacturers and suppliers provide a robust serialization solution based on the FDA's Drug Supply Chain Security Act.
Pharmaceutical Technology
FEBRUARY 13, 2024
Two FDA representatives FDA spoke at the ongoing 2024 SCOPE Summit about how the agency is focusing on AI.
Pharmaceutical Commerce
FEBRUARY 13, 2024
The analysis notes that 60% of respondents were setting targets based on AI’s ability to either cut costs or boost productivity.
PharmExec
FEBRUARY 13, 2024
Roche halts agreement with Repare Therapeutics to develop and commercialize camonsertib just weeks after triggering a $40 million milestone payment when the first patient was dosed with the novel cancer drug.
Pharmaceutical Commerce
FEBRUARY 13, 2024
Examination evaluates investigational stem cell interventions, including how the states have implemented their own policies when it comes to their uses.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
327 
Let's personalize your content